Cargando…
Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design
The study aimed to develop a new reverse-phase high-performance liquid chromatography (RP-HPLC) method with diode array detection (DAD) detection for simultaneous estimation of escitalopram (EST) and clonazepam (CZP) in tablet dosage forms with a quality by design (QbD) approach. The chromatographic...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268709/ https://www.ncbi.nlm.nih.gov/pubmed/35807458 http://dx.doi.org/10.3390/molecules27134209 |
_version_ | 1784744051764887552 |
---|---|
author | Foudah, Ahmed I. Alshehri, Sultan Shakeel, Faiyaz Alqarni, Mohammed H. Aljarba, Tariq M. Alam, Prawez |
author_facet | Foudah, Ahmed I. Alshehri, Sultan Shakeel, Faiyaz Alqarni, Mohammed H. Aljarba, Tariq M. Alam, Prawez |
author_sort | Foudah, Ahmed I. |
collection | PubMed |
description | The study aimed to develop a new reverse-phase high-performance liquid chromatography (RP-HPLC) method with diode array detection (DAD) detection for simultaneous estimation of escitalopram (EST) and clonazepam (CZP) in tablet dosage forms with a quality by design (QbD) approach. The chromatographic conditions were optimized by Box-Behnken design (BBD) and developed method was validated for the linearity, system suitability, accuracy, precision, robustness, sensitivity, and solution stability according to International Council for Harmonization (ICH) guidelines. EST and CZP standard drugs peaks were separated at retention times of 2.668 and 5.046 min by C-18 column with dimension of 4.6 × 100 mm length and particle size packing 2.5 µm. The mobile phase was methanol: 0.1% orthophosphoric acid (OPA) (25:75, v/v), with a flow rate of 0.7 mL/min at temperature of 26 °C. The sample volume injected was 20 µL and peaks were detected at 239 nm. Using the standard calibration curve, the % assay of marketed tablet was founded 98.89 and 98.76 for EST and CZP, respectively. The proposed RP-HPLC method was able to detect EST and CZP in the presence of their degradation products, indicating the stability-indicating property of the developed RP-HPLC method. The validation parameter’s results in terms of linearity, system suitability, accuracy, precision, robustness, sensitivity, and solution stability were in an acceptable range as per the ICH guidelines. The newly developed RP-HPLC method with QbD application is simple, accurate, time-saving, and economic. |
format | Online Article Text |
id | pubmed-9268709 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92687092022-07-09 Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design Foudah, Ahmed I. Alshehri, Sultan Shakeel, Faiyaz Alqarni, Mohammed H. Aljarba, Tariq M. Alam, Prawez Molecules Article The study aimed to develop a new reverse-phase high-performance liquid chromatography (RP-HPLC) method with diode array detection (DAD) detection for simultaneous estimation of escitalopram (EST) and clonazepam (CZP) in tablet dosage forms with a quality by design (QbD) approach. The chromatographic conditions were optimized by Box-Behnken design (BBD) and developed method was validated for the linearity, system suitability, accuracy, precision, robustness, sensitivity, and solution stability according to International Council for Harmonization (ICH) guidelines. EST and CZP standard drugs peaks were separated at retention times of 2.668 and 5.046 min by C-18 column with dimension of 4.6 × 100 mm length and particle size packing 2.5 µm. The mobile phase was methanol: 0.1% orthophosphoric acid (OPA) (25:75, v/v), with a flow rate of 0.7 mL/min at temperature of 26 °C. The sample volume injected was 20 µL and peaks were detected at 239 nm. Using the standard calibration curve, the % assay of marketed tablet was founded 98.89 and 98.76 for EST and CZP, respectively. The proposed RP-HPLC method was able to detect EST and CZP in the presence of their degradation products, indicating the stability-indicating property of the developed RP-HPLC method. The validation parameter’s results in terms of linearity, system suitability, accuracy, precision, robustness, sensitivity, and solution stability were in an acceptable range as per the ICH guidelines. The newly developed RP-HPLC method with QbD application is simple, accurate, time-saving, and economic. MDPI 2022-06-30 /pmc/articles/PMC9268709/ /pubmed/35807458 http://dx.doi.org/10.3390/molecules27134209 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Foudah, Ahmed I. Alshehri, Sultan Shakeel, Faiyaz Alqarni, Mohammed H. Aljarba, Tariq M. Alam, Prawez Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design |
title | Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design |
title_full | Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design |
title_fullStr | Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design |
title_full_unstemmed | Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design |
title_short | Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design |
title_sort | simultaneous estimation of escitalopram and clonazepam in tablet dosage forms using hplc-dad method and optimization of chromatographic conditions by box-behnken design |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268709/ https://www.ncbi.nlm.nih.gov/pubmed/35807458 http://dx.doi.org/10.3390/molecules27134209 |
work_keys_str_mv | AT foudahahmedi simultaneousestimationofescitalopramandclonazepamintabletdosageformsusinghplcdadmethodandoptimizationofchromatographicconditionsbyboxbehnkendesign AT alshehrisultan simultaneousestimationofescitalopramandclonazepamintabletdosageformsusinghplcdadmethodandoptimizationofchromatographicconditionsbyboxbehnkendesign AT shakeelfaiyaz simultaneousestimationofescitalopramandclonazepamintabletdosageformsusinghplcdadmethodandoptimizationofchromatographicconditionsbyboxbehnkendesign AT alqarnimohammedh simultaneousestimationofescitalopramandclonazepamintabletdosageformsusinghplcdadmethodandoptimizationofchromatographicconditionsbyboxbehnkendesign AT aljarbatariqm simultaneousestimationofescitalopramandclonazepamintabletdosageformsusinghplcdadmethodandoptimizationofchromatographicconditionsbyboxbehnkendesign AT alamprawez simultaneousestimationofescitalopramandclonazepamintabletdosageformsusinghplcdadmethodandoptimizationofchromatographicconditionsbyboxbehnkendesign |